Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 26
Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis
Y J Youn, Seung Yeon Kim, Hyun‐Jeong Jeong, et al.
Frontiers in Neuroendocrinology (2024) Vol. 73, pp. 101131-101131
Open Access | Times Cited: 23
Activation of SIRT1 by SRT1720 Alleviates Dyslipidemia, Improves Insulin Sensitivity and Exhibits Liver-Protective Effects in Diabetic Rats on a High-Fat Diet: New Insights into the SIRT1/Nrf2/NFκB Signaling Pathway
Elsayed A. Elmorsy, Hossam A. Elsisi, Abdullah S. Alkhamiss, et al.
European Journal of Pharmaceutical Sciences (2025) Vol. 206, pp. 107002-107002
Open Access | Times Cited: 4
Diabetes Mellitus Secondary to Endocrine Diseases: An Update of Diagnostic and Treatment Particularities
Mihaela Simona Popoviciu, Lorena Păduraru, Raluca Marinela Nutas, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12676-12676
Open Access | Times Cited: 27
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
Jiaqi Mei, Yi Li, Liyan Niu, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Obesity: the perfect storm for heart failure
Maria Lembo, Teresa Strisciuglio, Celeste Fonderico, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 4, pp. 1841-1860
Open Access | Times Cited: 12
Effect of supplementation with probiotics or synbiotics on cardiovascular risk factors in patients with metabolic syndrome: a systematic review and meta-analysis of randomized clinical trials
TingRui Chen, Jing Wang, ZeKun Liu, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 10
Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Alzheimer's Disease, Vascular Dementia, and Other Dementia Types Among Patients with Type 2 Diabetes
Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, et al.
Diabetes & Metabolism (2025), pp. 101623-101623
Closed Access | Times Cited: 1
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 1
Assessment of the Negative Factors for the Clinical Outcome in Patients with SARS-CoV-2 Infection and Type 2 Diabetes Mellitus
Oana Albai, Adina Braha, Bogdan Timar, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 271-282
Open Access | Times Cited: 8
SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art
David Aristizábal-Colorado, Martín Ocampo Posada, Wilfredo Antonio Rivera Martínez, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 6, pp. 707-718
Closed Access | Times Cited: 5
Incidence and predictors of chronic kidney disease among patients with diabetes treated at governmental hospitals of Harari Region, eastern Ethiopia, 2022
Abera Cheru, Dumessa Edessa, Lemma Demissie Regassa, et al.
Frontiers in Public Health (2024) Vol. 11
Open Access | Times Cited: 4
Risk factors for chronic kidney disease in middle eastern patients with type 2 diabetes mellitus: A cross-sectional study using the KDIGO classification
Randa Farah, Abdulrahman Alhajahjeh, Oraib Al-farahid, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 5, pp. 108740-108740
Closed Access | Times Cited: 4
Advances in the Insulin–Heart Axis: Current Therapies and Future Directions
Alfredo Caturano, Erica Vetrano, Raffaele Galiero, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10173-10173
Open Access | Times Cited: 4
Use of sodium‐glucose cotransporter‐2 inhibitors and risk of dementia: A population‐based cohort study
Lin Zhuo, Baixue Zhang, Yueqi Yin, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer’s disease in type 2 diabetes
Prakash Ramakrishan, Jayaraman Rajangam, Shaheedha Shabudeen Mahinoor, et al.
Metabolic Brain Disease (2025) Vol. 40, Iss. 3
Closed Access
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Ashot Avagimyan, Mohammad Sheibani, А. И. Трофименко, et al.
Innovative medicine of Kuban (2025) Vol. 10, Iss. 1, pp. 101-109
Open Access
Diabetes-induced edothelial dysfuction: Molecular pathways and clinical implication
Mohd Basheeruddin, Sana Qausain, Arvind Kumar Kushwaha, et al.
Multidisciplinary Reviews (2025) Vol. 8, Iss. 7, pp. 2025232-2025232
Closed Access
The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
Diego Rivas‐Otero, Tomás González‐Vidal, Pablo Agüeria‐Cabal, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
Keep your guard up: blood–brain barrier protection by empagliflozin after acute ischaemic stroke
Karin Hochrainer, Abby Hansen, Lidia García‐Bonilla
Cardiovascular Research (2025)
Closed Access
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, et al.
Pharmacology & Therapeutics (2025) Vol. 270, pp. 108861-108861
Open Access
Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments
Kazi Nazrul Islam, Rahib K. Islam, Ivan Nguyen, et al.
Advances in Therapy (2025)
Open Access
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Alessandro Cuttone, Vittorio Cannavò, Rana Abdullah, et al.
Cells (2025) Vol. 14, Iss. 9, pp. 668-668
Open Access
SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis
Qing Zhang, Zhiwen Deng, Tudi Li, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 10
Open Access | Times Cited: 3
The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs
Alex Wang, Xian Liang Zhou
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 4, pp. 563-573
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top